GBT

GBT is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies to bring hope to underserved patient populations. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily treatment for sickle cell disease.